Abevmy 100 mg/4 ml

Abevmy 100 mg/4 ml — Bevacizumab উপাদানসমৃদ্ধ আইভি ইনফিউশন। প্রস্তুতকারক: Beximco Pharmaceuticals Ltd.।

• Bevacizumab is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of:
• Metastatic colorectal cancer, with intravenous 5-fluorouracil-based chemotherapy for first-or second-line treatment.
• Metastatic colorectal cancer, with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for second-line treatment in patients who have progressed on a first-line Bevacizumab containing regimen.
• Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first-line treatment of unresectable, locally advanced, recurrent or metastatic disease.
• Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy. Effectiveness of Bevacizumab is based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Bevacizumab.
• Metastatic renal cell carcinoma with interferon alfa.
• Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.
• Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is: (1) Platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan. (2) Platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Bevacizumab as a single agent.
• Limitation of Use: Bevacizumab is not indicated for adjuvant treatment of colon cancer.